DOCSLIB.ORG

Glutamine: Fructose-6-Phosphate Aminotransferase 2 (GFPT2)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glutamine: Fructose-6-Phosphate Aminotransferase 2 (GFPT2) Glutamine: fructose-6-phosphate aminotransferase 2 (GFPT2) is a novel NF-B target that links cancer metabolism with metastatic phenotypes in non-small cell lung cancer Szymon Jakub Szymura Krakow, Poland M.Sc. Biotechnology, Jagiellonian University, 2010 M.Sc. Biochemistry, University of Virginia, 2012 A Dissertation Presented to the Graduate Faculty of the University of Virginia in Candidacy for the Degree of Doctor of Philosophy Department of Biochemistry and Molecular Genetics University of Virginia May 2016 ____________________________________ ____________________________________ ____________________________________ ____________________________________ i ABSTRACT Lung cancer is one of the most prevalent cancer types and the leading cause of cancer related mortality in the world. Non-small cell lung cancer (NSCLC) constitutes the majority of lung cancers with the five-year survival rate at 17%. Poor survival rates are due to late-stage diagnosis and limited response to standard of care cisplatin-based chemotherapy. Recent efforts in targeted therapy in lung cancer yielded limited success due to the activation of compensatory survival mechanisms and acquisition of drug resistance. Metastasis in NSCLC is driven by the trans-differentiation process called epithelial to mesenchymal transition (EMT) that promotes migratory and invasive phenotypes in cancer cells. EMT is induced by cytokines secreted by cells present in tumor microenvironment. The Mayo laboratory has shown that transforming growth factor beta (TGF) and tumor necrosis factor (TNF) cooperate to induce EMT in NSCLC and that activation of the nuclear factor kappa B (NF-B) pathway is essential for the transition. Cancer cells show elevated uptake and utilization of glucose and glutamine via aerobic glycolysis (Warburg effect) and anaplerotic TCA cycle respectively. Glucose and glutamine are both required for the synthesis of UDP-N-acetylglucosamine (UDP-GlcNAc) in the hexosamine biosynthesis pathway (HBP). UDP-GlcNAc is a precursor molecule for multiple processes including protein glycosylation, generation of glycosaminoglycans and O-GlcNAcylation of nucleocytoplasmic proteins. Aberrant elevation of glycans has been implicated in cancer progression, survival ii and metastasis. Glutamine: fructose-6-phosphate (GFPT) is a first and rate- limiting enzyme in HBP. Here we show that neuronal-specific GFPT2 isoform is a novel NF-B target, up-regulated during TNF/TGF-induced EMT in NSCLC and in response to MEK inhibition in KRAS-mutant NSCLC. GFPT2 induction elevates protein O-GlcNAcylation in mesenchymal cells and is required for the migration and invasion of mesenchymal NSCLC. Consistent with these observations high GFPT2 expression co-relates with poor clinical outcome of lung adenocarcinoma patients. iii ACKNOWLEDGEMENTS I would like to thank Dr. Marty Mayo for accepting me to his laboratory, helping me with my application to the UVA graduate school and being my mentor for the past years. I would like to thank him for his tremendous support and patience thorough my time in graduate school and for teaching me a great amount about cancer biology. I would like to thank Dr. Joel Hockensmith for accepting me into BMG program. I would like to thank Dr. Zygmunt Derewenda for leading a Polish student exchange program that gave me and others invaluable opportunity to study at the University of Virginia. I would like to thank my committee members: Dr. Stefan Bekiranov, Dr. David Kashatus and Dr. Patrick Grant for their constructive suggestions and encouragement. I would like to thank my former mentors Dr. Joanna Cichy and Dr. Derk Amsen for introducing me to the world of science and for being truly inspiring role models. I would like to thank Dr. David Allison for being my friend and mentor during my first years in the U.S. as well as Jackie D’Innocenzi for being a great friend, an inspiring human being and a brilliant labmate. I would also like to thank Jacob Zaemes for his great help and all present and former Mayo lab members including Sheena Clift, Lisa Gray, Brian McKenna, Jake Wamsley, Emily Glidden and others for their collaboration and help. Finally I would also like to thank Debbie Sites for her patience and help with all formalities of the graduate school. I would like to especially thank Ewelina Zasadzińska, and my family and friends for their support and understanding. iv TABLE OF CONTENTS Abstract i Acknowledgements iii Table of Contents iv List of Figures vii List of Abbreviations ix Chapter I: General Introduction 1 Lung Cancer 2 Metastasis and Epithelial to Mesenchymal Transition 7 Cancer Metabolism 12 Hexosamine Biosynthesis Pathway 19 Proteoglycans and Hyaluronan in Cancer Biology 24 N- and O-Glycosylation and Cancer Biology 29 O-GlcNAcylation in Cancer Biology 35 NF-B Pathway and Cancer 41 References 48 Chapter II: Materials and Methods 71 Cell Culture and Reagents 72 Plasmids and Cell Transfection 72 Viral Particle Production 73 Generation of Stable Cell Lines 74 Tumorsphere Cultures 75 ChIP-seq Data Analysis 76 Quantitative Real-Time Polymerase Chain Reaction v (QRT-PCR) and PCR 76 Chromatin Immunoprecipitation (ChIP) 76 Adenoviral Infections 77 Transwell migration and invasion assays and wound healing assays 78 Immunoprecipitation, succinylated Wheat Germ Agglutinin (sWGA) pull-down and Immunoblotting 79 Luciferase Reporter Assay 79 References 81 Chapter III: NF-B Upregulates Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) to Promote Migration in Non-Small Cell Lung Cancer 82 Abstract 84 Introduction 85 Results 88 OGT is required for EMT in A549 cells 88 Mesenchymal NSCLC cells upregulate genes involved in UDP-GlcNAc synthesis 91 Elevated GFPT2 expression correlates with poor clinical outcome in NSCLC 95 GFPT2 is an immediate-early gene product maintained in mesenchymal NSCLC cells 100 The GFPT2 gene is transcriptionally regulated by NF-B 104 GFPT2 regulates protein O-GlcNAcylation and migration of mesenchymal NSCLC cells 108 Discussion 112 References 118 Supplementary Figures 124 vi Chapter IV: NF-B, GFPT2 and hexosamine biosynthesis pathway are induced in response to MEK inhibition in KRAS-mutant Non-Small Cell Lung Cancer to promote chemoresistance 137 Abstract 138 Introduction 139 Results 142 MEK inhibition activates Akt and NF-B pathways in KRAS-mutant NSCLC cells 142 Inhibition of NF-B promotes apoptosis following MEK inhibition in KRAS-mutant LUAD cells 143 MEK inhibition induces protein O-GlcNAcylation and the expression of the GFPT2 gene 146 GFPT2 elevates protein O-GlcNAcylation and sustains NF-B signaling 152 Silencing of GFPT2 promotes cell death following MEK inhibition in KRAS-mutant LUAD cells 155 Discussion 159 References 162 Chapter V: Summary and Future Directions 166 Summary 167 Future Directions 169 Determine the mechanism of GFPT2-dependent effect on the migration of mesenchymal NSCLC cells 169 Determine the relevance of the GFPT2 induction in mesenchymal NSCLC cells in vivo 177 Determine the role of NF-B, GFPT2 and protein O-GlcNAcylation in the survival of KRAS-mutant NSCLC cells following MEK inhibition 182 References 189 vii LIST OF FIGURES Introduction Figure 1: Metabolic pathways of glucose and glutamine in a cancer cell 15 Table 1: Primer Sequences 82 Figure 1: OGT is required for epithelial to mesenchymal transition in NSCLC 89 Figure 2: O-GlcNAcylation and enzymes involved in the synthesis of UDP-GlcNAc are elevated in mesenchymal NSCLC 92 Figure 3: GFPT2 is induced in mesenchymal NSCLC cells and is co-expressed with mesenchymal markers in LUAD patients 96 Figure 4: GFPT2 is an immediate-early gene induced by TNF and maintained in mesenchymal NSCLC 101 Figure 5: GFPT2 is a direct target of NF-B 105 Figure 6: GFPT2 regulates migration of mesenchymal NSCLC 109 Supplementary Figure S1: GFPT1 expression in mesenchymal NSCLC 125 Supplementary Figure S2: Epigenetic landscape of the proximal promoter of GFPT2 confirms the location of the NF-B enhancer within the body of the gene locus 127 Supplementary Figure S3: GFPT2 knock-down does not affect EMT in NSCLC 129 Supplementary Figure S4: siRNA-mediated silencing of GFPT2 reduces migration of H1299 NSCLC cells 131 Supplementary Figure S5: O-GlcNAcylation of p65 is elevated in mesenchymal NSCLC cells 133 Figure 7: MEK inhibition activates Akt and NF-B pathways in KRAS-mutant NSCLC cells 142 Figure 8: NF-B activation is required for the survival of KRAS-mutant NSCLC cells following MEK inhibition 145 viii Figure 9: MEK inhibition induces protein O-GlcNAcylation and GFPT2 expression 148 Figure 10: GFPT2 potentiates NF-B signaling in vitro 151 Figure 11: GFPT2 is required for the survival of KRAS-mutant NSCLC cells following MEK inhibition 155 Figure 12: Mesenchymal NSCLC upregulate genes involved in the synthesis of glycans and show elevated multi-branched N-glycosylation 192 Figure 13: GFPT2 interacts with components of the migratory and endocytic machinery 194 ix LIST OF ABBREVIATIONS ADC - adenocarcinoma CIC – cancer initiating cells ECM – extracellular matrix EMT – epithelial to mesenchymal transition GAG - glycosaminoglycan GAPDH - glyceraldehyde-3-phosphate dehydrogenase GFPT – glutamine fructose-6-phosphate aminotransferase HA - hyaluronan HAS – hyaluronan synthase HBP – hexosamine biosynthesis pathway HIF1a – hypoxia-inducible factor 1-alpha IKK – IB kinase NF-kB – nuclear factor kappa B NSCLC – non-small cell lung cancer OGA – O-GlcNAcase OGT – O-linked N-acetylglucosamine (GlcNAc) transferase PG - proteoglycan SCC – squamous cell carcinoma SCLC – small cell lung cancer
Load more

Recommended publications
  • Causes and Evaluation of Mildly Elevated Liver Transaminase Levels ROBERT C
    Causes and Evaluation of Mildly Elevated Liver Transaminase Levels ROBERT C. OH, LTC, MC, USA, and THOMAS R. HUSTEAD, LTC, MC, USA Tripler Army Medical Center Family Medicine Residency Program, Honolulu, Hawaii Mild elevations in levels of the liver enzymes alanine transaminase and aspartate transaminase are commonly dis- covered in asymptomatic patients in primary care. Evidence to guide the diagnostic workup is limited. If the history and physical examination do not suggest a cause, a stepwise evaluation should be initiated based on the prevalence of diseases that cause mild elevations in transaminase levels. The most common cause is nonalcoholic fatty liver disease, which can affect up to 30 percent of the population. Other common causes include alcoholic liver disease, medication- associated liver injury, viral hepatitis (hepatitis B and C), and hemochromatosis. Less common causes include α1-antitrypsin deficiency, autoimmune hepatitis, and Wilson disease. Extrahepatic conditions (e.g., thyroid disorders, celiac disease, hemolysis, muscle disorders) can also cause elevated liver transaminase levels. Initial testing should include a fasting lipid profile; measurement of glucose, serum iron, and ferritin; total iron-binding capacity; and hepa- titis B surface antigen and hepatitis C virus antibody testing. If test results are normal, a trial of lifestyle modification with observation or further testing for less common causes is appropriate. Additional testing may include ultrasonog- raphy; measurement of α1-antitrypsin and ceruloplasmin; serum protein electrophoresis; and antinuclear antibody, smooth muscle antibody, and liver/kidney microsomal antibody type 1 testing. Referral for further evaluation and possible liver biopsy is recommended if transaminase levels remain elevated for six months or more.
    [Show full text]
  • High-Throughput Discovery of Novel Developmental Phenotypes
    High-throughput discovery of novel developmental phenotypes The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Dickinson, M. E., A. M. Flenniken, X. Ji, L. Teboul, M. D. Wong, J. K. White, T. F. Meehan, et al. 2016. “High-throughput discovery of novel developmental phenotypes.” Nature 537 (7621): 508-514. doi:10.1038/nature19356. http://dx.doi.org/10.1038/nature19356. Published Version doi:10.1038/nature19356 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071918 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2017 March 14. Published in final edited form as: Nature. 2016 September 22; 537(7621): 508–514. doi:10.1038/nature19356. High-throughput discovery of novel developmental phenotypes A full list of authors and affiliations appears at the end of the article. Abstract Approximately one third of all mammalian genes are essential for life. Phenotypes resulting from mouse knockouts of these genes have provided tremendous insight into gene function and congenital disorders. As part of the International Mouse Phenotyping Consortium effort to generate and phenotypically characterize 5000 knockout mouse lines, we have identified 410 Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms #Corresponding author: [email protected].
    [Show full text]
  • Supp Material.Pdf
    Simon et al. Supplementary information: Table of contents p.1 Supplementary material and methods p.2-4 • PoIy(I)-poly(C) Treatment • Flow Cytometry and Immunohistochemistry • Western Blotting • Quantitative RT-PCR • Fluorescence In Situ Hybridization • RNA-Seq • Exome capture • Sequencing Supplementary Figures and Tables Suppl. items Description pages Figure 1 Inactivation of Ezh2 affects normal thymocyte development 5 Figure 2 Ezh2 mouse leukemias express cell surface T cell receptor 6 Figure 3 Expression of EZH2 and Hox genes in T-ALL 7 Figure 4 Additional mutation et deletion of chromatin modifiers in T-ALL 8 Figure 5 PRC2 expression and activity in human lymphoproliferative disease 9 Figure 6 PRC2 regulatory network (String analysis) 10 Table 1 Primers and probes for detection of PRC2 genes 11 Table 2 Patient and T-ALL characteristics 12 Table 3 Statistics of RNA and DNA sequencing 13 Table 4 Mutations found in human T-ALLs (see Fig. 3D and Suppl. Fig. 4) 14 Table 5 SNP populations in analyzed human T-ALL samples 15 Table 6 List of altered genes in T-ALL for DAVID analysis 20 Table 7 List of David functional clusters 31 Table 8 List of acquired SNP tested in normal non leukemic DNA 32 1 Simon et al. Supplementary Material and Methods PoIy(I)-poly(C) Treatment. pIpC (GE Healthcare Lifesciences) was dissolved in endotoxin-free D-PBS (Gibco) at a concentration of 2 mg/ml. Mice received four consecutive injections of 150 μg pIpC every other day. The day of the last pIpC injection was designated as day 0 of experiment.
    [Show full text]
  • Gamma Glutamyl Transferase (GGT) NCD 190.32
    Medicare National Coverage Determination (NCD) Policy TRANSFERASE GAMMA GLUTAMYL Summary: Gamma Glutamyl Transferase (GGT) NCD 190.32 The terms of Medicare National Coverage Determinations (NCDs) are binding on all fee-for-service (Part A/B) Medicare Administrative Contractors (MACs) and Medicare Advantage (MA) plans. NCDs are not binding, however, on Medicaid and other governmental payers, nor are they binding on commercial payers in their non-MA lines of business. Item/Service Description* Gamma Glutamyl Transferase (GGT) is an intracellular enzyme that appears in blood following leakage from cells. Renal tubules, liver, and pancreas contain high amounts, although the measurement of GGT in serum is almost always used for assessment of hepatobiliary function. Unlike other enzymes which are found in heart, skeletal muscle, and intestinal mucosa as well as liver, the appearance of an elevated level of GGT in serum is almost always the result of liver disease or injury. It is specifically useful to differentiate elevated alkaline phosphatase levels when the source of the alkaline phosphatase increase (bone, liver, or placenta) is unclear. The combination of high alkaline phosphatase and a normal GGT does not, however, rule out liver disease completely. As well as being a very specific marker of hepatobiliary function, GGT is also a very sensitive marker for hepatocellular damage. Abnormal concentrations typically appear before elevations of other liver enzymes or bilirubin are evident. Obstruction of the biliary tract, viral infection (e.g., hepatitis, mononucleosis), metastatic cancer, exposure to hepatotoxins (e.g., organic solvents, drugs, alcohol), and use of drugs that induce microsomal enzymes in the liver (e.g., cimetidine, barbiturates, phenytoin, and carbamazepine) all can cause a moderate to marked increase in GGT serum concentration.
    [Show full text]
  • Como As Enzimas Agem?
    O que são enzimas? Catalizadores biológicos - Aceleram reações químicas específicas sem a formação de produtos colaterais PRODUTO SUBSTRATO COMPLEXO SITIO ATIVO ENZIMA SUBSTRATO Características das enzimas 1 - Grande maioria das enzimas são proteínas (algumas moléculas de RNA tem atividade catalítica) 2 - Funcionam em soluções aquosas diluídas, em condições muito suaves de temperatura e pH (mM, pH neutro, 25 a 37oC) Pepsina estômago – pH 2 Enzimas de organismos hipertermófilos (crescem em ambientes quentes) atuam a 95oC 3 - Apresentam alto grau de especificidade por seus reagentes (substratos) Molécula que se liga ao sítio ativo Região da enzima e que vai sofrer onde ocorre a a ação da reação = sítio ativo enzima = substrato 4 - Peso molecular: varia de 12.000 à 1 milhão daltons (Da), são portanto muito grandes quando comparadas ao substrato. 5 - A atividade catalítica das Enzimas depende da integridade de sua conformação protéica nativa – local de atividade catalítica (sitio ativo) Sítio ativo e toda a molécula proporciona um ambiente adequado para ocorrer a reação química desejada sobre o substrato A atividade de algumas enzimas podem depender de outros componentes não proteicos Enzima ativa = Holoenzimas Parte protéica das enzimas + cofator Apoenzima ou apoproteína •Íon inorgânico •Molécula complexa (coenzima) Covalentemente ligados à apoenzima GRUPO PROSTÉTICO COFATORES Elemento com ação complementar ao sitio ativo as enzimas que auxiliam na formação de um ambiente ideal para ocorrer a reação química ou participam diretamente dela
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]
  • New Insight on FGFR3-Related Chondrodysplasias Molecular Physiopathology Revealed by Human Chondrocyte Gene Expression Profiling
    New insight on FGFR3-related chondrodysplasias molecular physiopathology revealed by human chondrocyte gene expression profiling Laurent Schibler, Linda Gibbs, Catherine Benoist-Lasselin, Charles Decraene, Jelena Martinovic, Philippe Loget, Anne-Lise Delezoide, Marie Gonzales, Arnold Munnich, Jean-Philippe Jais, et al. To cite this version: Laurent Schibler, Linda Gibbs, Catherine Benoist-Lasselin, Charles Decraene, Jelena Martinovic, et al.. New insight on FGFR3-related chondrodysplasias molecular physiopathology revealed by human chondrocyte gene expression profiling. PLoS ONE, Public Library of Science, 2009, 4, online (10), Non paginé. 10.1371/journal.pone.0007633. hal-01193364 HAL Id: hal-01193364 https://hal.archives-ouvertes.fr/hal-01193364 Submitted on 30 May 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. New Insight on FGFR3-Related Chondrodysplasias Molecular Physiopathology Revealed by Human Chondrocyte Gene Expression Profiling Laurent Schibler1,2, Linda Gibbs1,3, Catherine Benoist-Lasselin1, Charles Decraene4, Jelena Martinovic5,
    [Show full text]
  • Relationship of Liver Enzymes to Insulin Sensitivity and Intra-Abdominal Fat
    Diabetes Care Publish Ahead of Print, published online July 31, 2007 Relationship of Liver Enzymes to Insulin Sensitivity and Intra-abdominal Fat Tara M Wallace MD*, Kristina M Utzschneider MD*, Jenny Tong MD*, 1Darcy B Carr MD, Sakeneh Zraika PhD, 2Daniel D Bankson MD, 3Robert H Knopp MD, Steven E Kahn MB, ChB. *Metabolism, Endocrinology and Nutrition, VA Puget Sound Health Care System 1Obstetrics and Gynecology, University of Washington, Seattle, WA 2Pathology and Laboratory Medicine, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, WA 3Harborview Medical Center, University of Washington, Seattle, WA Running title: Liver enzymes and insulin sensitivity Correspondence to: Steven E. Kahn, M.B., Ch.B. VA Puget Sound Health Care System (151) 1660 S. Columbian Way Seattle, WA 98108 Email: [email protected] Received for publication 18 August 2006 and accepted in revised form 29 June 2007. 1 Copyright American Diabetes Association, Inc., 2007 Liver enzymes and insulin sensitivity ABSTRACT Objective: To determine the relationship between plasma liver enzyme concentrations, insulin sensitivity and intra-abdominal fat (IAF) distribution. Research Design and Methods: Plasma gamma-glutamyl transferase (GGT), aspartate transaminase (AST), alanine transaminase (ALT) levels, insulin sensitivity (SI), IAF and subcutaneous fat (SCF) areas were measured on 177 non-diabetic subjects (75M/102, 31-75 2 -5 years) with no history of liver disease. Based on BMI (< or ≥27.5 kg/m ) and SI (< or ≥7.0x10 min-1 pM-1) subjects were divided into lean insulin sensitive (LIS, n=53), lean insulin resistant (LIR, n=60) and obese insulin resistant (OIR, n=56) groups.
    [Show full text]
  • GFAT and PFK Genes Show Contrasting Regulation of Chitin
    www.nature.com/scientificreports OPEN GFAT and PFK genes show contrasting regulation of chitin metabolism in Nilaparvata lugens Cai‑Di Xu1,3, Yong‑Kang Liu2,3, Ling‑Yu Qiu2, Sha‑Sha Wang2, Bi‑Ying Pan2, Yan Li2, Shi‑Gui Wang2 & Bin Tang2* Glutamine:fructose‑6‑phosphate aminotransferase (GFAT) and phosphofructokinase (PFK) are enzymes related to chitin metabolism. RNA interference (RNAi) technology was used to explore the role of these two enzyme genes in chitin metabolism. In this study, we found that GFAT and PFK were highly expressed in the wing bud of Nilaparvata lugens and were increased signifcantly during molting. RNAi of GFAT and PFK both caused severe malformation rates and mortality rates in N. lugens. GFAT inhibition also downregulated GFAT, GNPNA, PGM1, PGM2, UAP, CHS1, CHS1a, CHS1b, Cht1-10, and ENGase. PFK inhibition signifcantly downregulated GFAT; upregulated GNPNA, PGM2, UAP, Cht2‑4, Cht6‑7 at 48 h and then downregulated them at 72 h; upregulated Cht5, Cht8, Cht10, and ENGase; downregulated Cht9 at 48 h and then upregulated it at 72 h; and upregulated CHS1, CHS1a, and CHS1b. In conclusion, GFAT and PFK regulated chitin degradation and remodeling by regulating the expression of genes related to the chitin metabolism and exert opposite efects on these genes. These results may be benefcial to develop new chitin synthesis inhibitors for pest control. Chitin is a linear polymer composed of N-acetylglucosamine units connected by β-1, 4-glycoside bonds and is the second most abundant biopolymer in nature. It is widely distributed in fungi, nematodes, and arthropods1. In insects, chitin is a major component of the exoskeleton, trachea, and the peritrophic matrix that lines the midgut epithelium1–4.
    [Show full text]
  • Alanine Transaminase Assay (ALT) Catalog #8478 100 Tests in 96-Well Plate
    Alanine Transaminase Assay (ALT) Catalog #8478 100 Tests in 96-well plate Product Description Alanine Aminotransferase (ALT), also known as serum glutamic-pyruvic transaminase (SGPT), catalyzes the reversible transfer of an amino group from alanine to α-ketoglutarate. The products of this transamination reaction are pyruvate and glutamate. ALT is found primarily in liver and serum, but occurs in other tissues as well. Significantly elevated serum ALT levels often suggest the existence of medical problems, such as hepatocellular injury, hepatitis, diabetes, bile duct problem and myopathy. This colorimetric assay is based on the oxidization of NADH to NAD in the presence of pyruvate and lactate dehydrogenase. The ALT activity is determined by assaying the rate of NADH oxidation, which is proportional to the reduction in absorbance at 340nm over time (ΔOD340nm/min). Kit Components Cat. No. # of vials Reagent Quantity Storage 8478a 1 Assay buffer 10 mL -20°C 8478b 1 ALT standard 10 µL -20°C 8478c 1 Substrate mix 1.0 mL -20°C 8478d 1 Cofactor 0.8 mL -20°C 8478e 1 Enzyme 0.2 mL -80°C Product Use The ALT kit measures the alanine transaminase activity of different types of samples, such as serum, plasma and tissues. ALT is for research use only. It is not approved for human or animal use, or for application in in vitro diagnostic procedures. Quality Control Serially diluted alanine transaminase solutions with concentrations ranging from 0.03125 to 1.0 U/mL are measured with the ScienCell™ Alanine Transaminase Assay kit. The decrease in OD340nm is monitored as a function of time (Figure 1) and the resulting standard of ∆OD340nm/min vs alanine transaminase activity are plotted (Figure 2).
    [Show full text]
  • Pyridoxine (Pyridoxamine) 5'-Phosphate Oxidase In
    PYRIDOXINE (PYRIDOXAMINE) 5’-PHOSPHATE OXIDASE IN ARABIDOPSIS THALIANA Except where reference is made to the work of others, the work described in this dissertation is my own or was done in collaboration with my advisory committee. This dissertation does not include proprietary or classified information. Yuying Sang Certificate of Approval: Robert D. Locy Narendra K. Singh, Chair Professor Professor Biological Sciences Biological Sciences Joe H. Cherry Joanna Wysocka-Diller Emeritus Professor Associate Professor Biological Sciences Biological Sciences Fenny Dane George T. Flowers Professor Dean Horticulture Graduate School PYRIDOXINE (PYRIDOXAMINE) 5’-PHOSPHATE OXIDASE IN ARABIDOPSIS THALIANA Yuying Sang A Dissertation Submitted to the Graduate Faculty of Auburn University in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Auburn, Alabama December 19, 2008 PYRIDOXINE (PYRIDOXAMINE) 5’-PHOSPHATE OXIDASE IN ARABIDOPSIS THALIANA Yuying Sang Permission is granted to Auburn University to make copies of this dissertation at its discretion, upon request of individuals of institutions and at their expense. The author reserves all publication right. Signature of Author Date of Graduation iii VITA Yuying Sang, daughter of Shiqing Sang and Guilan Wang, was born on January 7, 1975, in Chiping, Shandong, People’s Republic of China. She received the Bachelor of Science degree in Biology in July 1997 from Shandong Normal University and entered the Graduate School of Kunming Institute of Botany, Chinese Academy of Sciences. In the July of 2000, she graduated with a Master of Science degree in Botany and joined East China University of Science and Technology as a lab manager in the Department of Bioengineering.
    [Show full text]